Your browser doesn't support javascript.
loading
Risk Factors for Ebola Virus Persistence in Semen of Survivors in Liberia.
Dyal, Jonathan; Kofman, Aaron; Kollie, Jomah Z; Fankhauser, John; Orone, Romeo; Soka, Moses J; Glaybo, Uriah; Kiawu, Armah; Freeman, Edna; Giah, Giovanni; Tony, Henry D; Faikai, Mylene; Jawara, Mary; Kamara, Kuku; Kamara, Samuel; Flowers, Benjamin; Kromah, Mohammed L; Desamu-Thorpe, Rodel; Graziano, James; Brown, Shelley; Morales-Betoulle, Maria E; Cannon, Deborah L; Su, Kaihong; Linderman, Susanne L; Plucinski, Mateusz; Rogier, Eric; Bradbury, Richard S; Secor, W Evan; Bowden, Katherine E; Phillips, Christi; Carrington, Mary N; Park, Yeon-Hwa; Martin, Maureen P; Aguinaga, Maria Del Pilar; Mushi, Robert; Haberling, Dana L; Ervin, Elizabeth D; Klena, John D; Massaquoi, Moses; Nyenswah, Tolbert; Nichol, Stuart T; Chiriboga, David E; Williams, Desmond E; Hinrichs, Steven H; Ahmed, Rafi; Vonhm, Benjamin T; Rollin, Pierre E; Purpura, Lawrence J; Choi, Mary J.
Afiliación
  • Dyal J; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kofman A; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kollie JZ; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Fankhauser J; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Orone R; Men's Health Screening Program, Monrovia, Liberia.
  • Soka MJ; ELWA Hospital, Samaritan's Purse, Monrovia, Liberia.
  • Glaybo U; ELWA Hospital, Samaritan's Purse, Monrovia, Liberia.
  • Kiawu A; ELWA Hospital, Samaritan's Purse, Monrovia, Liberia.
  • Freeman E; Men's Health Screening Program, Monrovia, Liberia.
  • Giah G; Men's Health Screening Program, Monrovia, Liberia.
  • Tony HD; Men's Health Screening Program, Monrovia, Liberia.
  • Faikai M; Men's Health Screening Program, Monrovia, Liberia.
  • Jawara M; Men's Health Screening Program, Monrovia, Liberia.
  • Kamara K; Men's Health Screening Program, Monrovia, Liberia.
  • Kamara S; Men's Health Screening Program, Monrovia, Liberia.
  • Flowers B; Men's Health Screening Program, Monrovia, Liberia.
  • Kromah ML; Men's Health Screening Program, Monrovia, Liberia.
  • Desamu-Thorpe R; Men's Health Screening Program, Monrovia, Liberia.
  • Graziano J; Men's Health Screening Program, Monrovia, Liberia.
  • Brown S; Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Morales-Betoulle ME; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Cannon DL; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Su K; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Linderman SL; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Plucinski M; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Rogier E; Emory Vaccine Center, Emory University, Atlanta, Georgia, USA.
  • Bradbury RS; Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Secor WE; Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Bowden KE; Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Phillips C; Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Carrington MN; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Park YH; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Martin MP; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
  • Aguinaga MDP; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Mushi R; Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
  • Haberling DL; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
  • Ervin ED; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
  • Klena JD; Department of Internal Medicine, Meharry Sickle Cell Center, Meharry Medical College, Nashville, Tennessee, USA.
  • Massaquoi M; Department of Obstetrics and Gynecology, Meharry Sickle Cell Center, Nashville, Tennessee, USA.
  • Nyenswah T; Department of Internal Medicine, Meharry Sickle Cell Center, Meharry Medical College, Nashville, Tennessee, USA.
  • Nichol ST; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Chiriboga DE; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Williams DE; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Hinrichs SH; Ministry of Health, Liberia.
  • Ahmed R; Ministry of Health, Liberia.
  • Vonhm BT; Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rollin PE; University of Massachusetts Medical School, Worcester, Massachusetts, USA.
  • Purpura LJ; Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Choi MJ; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Clin Infect Dis ; 76(3): e849-e856, 2023 02 08.
Article en En | MEDLINE | ID: mdl-35639875
ABSTRACT

BACKGROUND:

Long-term persistence of Ebola virus (EBOV) in immunologically privileged sites has been implicated in recent outbreaks of Ebola virus disease (EVD) in Guinea and the Democratic Republic of Congo. This study was designed to understand how the acute course of EVD, convalescence, and host immune and genetic factors may play a role in prolonged viral persistence in semen.

METHODS:

A cohort of 131 male EVD survivors in Liberia were enrolled in a case-case study. "Early clearers" were defined as those with 2 consecutive negative EBOV semen test results by real-time reverse-transcription polymerase chain reaction (rRT-PCR) ≥2 weeks apart within 1 year after discharge from the Ebola treatment unit or acute EVD. "Late clearers" had detectable EBOV RNA by rRT-PCR >1 year after discharge from the Ebola treatment unit or acute EVD. Retrospective histories of their EVD clinical course were collected by questionnaire, followed by complete physical examinations and blood work.

RESULTS:

Compared with early clearers, late clearers were older (median, 42.5 years; P < .001) and experienced fewer severe clinical symptoms (median 2, P = .006). Late clearers had more lens opacifications (odds ratio, 3.9 [95% confidence interval, 1.1-13.3]; P = .03), after accounting for age, higher total serum immunoglobulin G3 (IgG3) titers (P = .005), and increased expression of the HLA-C*0304 allele (0.14 [.02-.70]; P = .007).

CONCLUSIONS:

Older age, decreased illness severity, elevated total serum IgG3 and HLA-C*0304 allele expression may be risk factors for the persistence of EBOV in the semen of EVD survivors. EBOV persistence in semen may also be associated with its persistence in other immunologically protected sites, such as the eye.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fiebre Hemorrágica Ebola / Ebolavirus Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans / Male País/Región como asunto: Africa Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fiebre Hemorrágica Ebola / Ebolavirus Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans / Male País/Región como asunto: Africa Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos